Says making “significant progress” with transformation programs. Sees FY26 CapEx $0.5B. Sees 2H26 revenue “slightly higher” than 1H26. Expects margins, free cash flow to “gradually ramp up” through FY26.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva says ‘exciting growth’ emerging from biosimilar portfolio
- Teva sees FY26 adjusted EPS $2.57-$2.77, consensus $2.77
- Teva ‘continues to execute’ on pillars of ‘Pivot to Growth’ strategy
- Teva reports Q4 non-GAAP EPS 96c, consensus 64c
- Teva parnters iwth Will Forte to increase awareness of Huntington’s disease